Episode 52: Daiichi Sankyo

In this episode of Petri Dish Perspectives: Biotech Unleashed, we break down the rise of Daiichi Sankyo, a company that quietly transformed itself from a cardiovascular powerhouse into one of the most dominant players in modern oncology.

This isn’t your typical biotech story. There’s no overnight success, no single “eureka” moment. Instead, we trace a century-long evolution, from the pioneering work of Jokichi Takamine and the early days of enzyme therapeutics, to the merger that unified biological extraction with synthetic chemistry, and ultimately to the company’s bold, high-stakes bet on antibody-drug conjugates (ADCs).

At the center of it all is Enhertu, the drug that shattered the traditional HER2 classification and redefined how we think about targeting cancer. We unpack how Daiichi Sankyo solved the ADC “linker problem,” engineered a platform with unmatched precision, and built a pipeline that’s now reshaping treatment across breast, lung, and gastric cancers.

We also explore the strategic partnerships with AstraZeneca and Merck & Co., and what they signal about Daiichi Sankyo’s position as a true platform leader in the ADC gold rush.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

https://linktr.ee/maneadkhin

#Biotech #DaiichiSankyo #ADC #AntibodyDrugConjugates #Oncology #DrugDevelopment #Pharma #Enhertu #LifeSciences #BiotechPodcast #PetriDishPerspectives

Transcript

Hello and welcome to Petri Dish Perspectives, the podcast where we geek out about science and the companies shaping the future of healthcare. I’m your host, Manead, and I’m a PhD scientist by training, a storyteller by choice. With every new episode released on Thursday, my goal is to deliver digestible pieces of information on healthcare companies under 30 mins.

To truly understand Daiichi Sankyo, you have to abandon the conventional biotech narrative of breakthrough moments and instead think like a systems engineer. This is not a company built on a single discovery, a charismatic founder, or a venture-backed sprint to IPO. It is a layered biological-industrial system, assembled piece by piece over more than a century.

Where many Western biotech firms operate on a “binary” model—high-risk discovery followed by either exponential success or collapse—Daiichi Sankyo represents a fundamentally different paradigm: cumulative innovation. Each generation of science didn’t replace the last; it was integrated into an expanding architecture that now spans enzyme engineering, small-molecule chemistry, and biologics.

What looks today like an overnight success in oncology is, in reality, the output of a 100-year R&D stack—one that began with fermentation vats and now culminates in precision-engineered antibody-drug conjugates (ADCs).

Quick disclaimer, I give full credit to the original articles cited in the references in the transcript!

Grab a coffee or tea, settle in, and let’s jump in!

The Chemical Genesis: Adrenaline and the Rise of a Scientific Translator

The story begins not in a modern lab, but at the intersection of East and West at the turn of the 20th century—with Jokichi Takamine.

Takamine is often described as the “Japanese Pasteur,” but that undersells his role. He wasn’t just a scientist—he was an early architect of biotech commercialization. At a time when Western medicine was still formalizing biochemical pathways, Takamine was translating centuries-old Japanese fermentation practices into industrial-scale biochemistry.

His first major success, Taka-Diastase, derived from Aspergillus oryzae, wasn’t just a digestive aid—it was a proof-of-concept for enzyme therapeutics at scale. By licensing it to Parke-Davis, Takamine effectively executed one of the earliest biotech licensing deals in history, generating capital and, more importantly, validating that biology could be monetized reproducibly.

But his true scientific milestone came in 1901: the isolation of adrenaline (epinephrine), the first hormone ever crystallized from a gland. This was more than a discovery—it was the birth of endocrine pharmacology, proving that internal biological signals could be extracted, stabilized, and deployed as drugs.

This dual capability—extract biology, then industrialize it—became the foundational logic of Sankyo.

Parallel Evolution: Synthetic Chemistry as the Second Pillar

While Sankyo was mastering biological extraction, a parallel force was emerging: Daiichi Pharmaceutical.

Founded in 1915, Daiichi took the opposite approach. Where Sankyo looked to nature, Daiichi looked to the lab bench. Their early success came from domesticating the synthesis of Salvarsan, the first effective treatment for syphilis originally developed by Paul Ehrlich.

This wasn’t just about manufacturing—it was about chemical sovereignty. Japan, at the time, was heavily dependent on Western imports for advanced medicines. Daiichi’s ability to reproduce and scale complex synthetic drugs locally marked the beginning of Japan’s pharmaceutical independence.

For nearly a century, these two entities evolved in parallel:

• Sankyo → Biological systems, enzymes, fermentation
• Daiichi → Synthetic chemistry, precision molecules

Independently powerful, but incomplete.

The 2005 Merger: Converging Two Scientific Lineages

The 2005-2007 merger creating Daiichi Sankyo was primarily triggered by the need to strengthen R&D capabilities, cope with intense competition in the pharmaceutical industry, and manage high costs associated with developing new drugs. The merger of Sankyo and Daiichi Pharmaceutical allowed the new entity to become a "Japan-based Global Pharma Innovator.

When the two companies merged in 2005 to form Daiichi Sankyo, it wasn’t just a corporate consolidation—it was the fusion of two technological paradigms.

Daiichi Sankyo was established on September 28, 2005, through the merger of Daiichi Pharmaceutical Co., Ltd. and Sankyo Company, Limited. It was not a traditional IPO, but a joint holding company establishment via a stock transfer listing on the Tokyo, Osaka, and Nagoya Stock Exchanges. As a merger, it was a stock transfer rather than a cash-raising IPO.

At the time, the strategic driver was survival. The global pharmaceutical industry was entering the “patent cliff” era, where blockbuster small molecules were losing exclusivity and generics were eroding margins at scale.

Daiichi Sankyo’s answer wasn’t to double down on volume—it was to redefine its core architecture.

Still, in the immediate term, the company leaned heavily on its cardiovascular franchise:

• Pravastatin → one of the earliest statins, foundational in lipid management
• Benicar (olmesartan) → a blockbuster ARB in hypertension
• Lixiana/Savaysa (edoxaban) → a Factor Xa inhibitor competing in the anticoagulant space

These drugs generated the cash flow substrate—the metabolic energy of the company—that would later fund a much riskier transformation.

But leadership recognized a structural reality: cardiovascular small molecules were becoming commoditized assets. The competitive moat was collapsing.

They needed a third pillar—not incremental, but transformative.

Takashi Shoda was from Sankyo and went on to lead the merged entity, Daiichi Sankyo Company, Limited. He served as the President and CEO of Sankyo Company, Ltd. before becoming the President and Representative Director of the newly established Daiichi Sankyo in 2005, following the merger with Daiichi Pharmaceutical Co., Ltd..

The Strategic Bet: Solving the ADC “Linker Problem”

Instead of acquiring innovation externally, Daiichi Sankyo made a decision that, in hindsight, defines the company: they chose to build a platform internally, targeting one of the most notoriously difficult problems in oncology—antibody-drug conjugates.

At the time, ADCs were widely considered a failed modality. Early attempts had been plagued by instability, toxicity, and poor targeting. The industry narrative was simple: great idea, flawed execution.

Daiichi Sankyo saw it differently. They didn’t view ADCs as broken—they viewed them as incomplete systems.

So they focused on three engineering constraints:

1. Payload Optimization
 They selected a derivative of exatecan (DXd), a topoisomerase I inhibitor with significantly higher potency than earlier payloads. This wasn’t just about strength—it was about precision lethality at low doses.

2. Linker Stability and Specificity
 The real breakthrough came here. Their tetrapeptide linker is stable in circulation but cleaved efficiently by lysosomal enzymes like cathepsins once internalized. This solved the central paradox: circulate safely, activate precisely.

3. Drug-to-Antibody Ratio (DAR)
 By pushing DAR to ~8, they effectively doubled payload delivery without compromising pharmacokinetics. This is a non-trivial achievement—it required rebalancing hydrophobicity, stability, and antibody integrity.

The result was a system capable of generating a powerful bystander effect—allowing the cytotoxic payload to diffuse into neighboring tumor cells, even those with low or absent target expression.

This single feature redefined the clinical utility of ADCs.

The Inflection Point: Enhertu and the Collapse of Binary Oncology

Everything changed with Enhertu (trastuzumab deruxtecan).

When AstraZeneca partnered with Daiichi Sankyo in 2019, they weren’t just buying into a drug—they were buying into a new ontology of cancer classification.

Historically, HER2 expression was binary: positive or negative. Treatment decisions were rigidly stratified.

Enhertu shattered that model.

By demonstrating efficacy in “HER2-low” patients, it expanded the treatable population dramatically and introduced a new paradigm: continuum-based targeting.

Clinically, this was profound. Commercially, it was explosive.

Enhertu rapidly expanded across indications:

• Breast cancer (HER2+ and HER2-low)
• Gastric cancer
• Non-small cell lung cancer

And it didn’t stop there. The pipeline followed:

• Datopotamab deruxtecan (TROP2)
• Patritumab deruxtecan (HER3)

Together, these assets form not just a portfolio, but a modular oncology platform.

The 2026 Landscape: Platform Dominance and Strategic Alliances

By 2026, Daiichi Sankyo has transitioned from participant to platform leader.

The multi-billion-dollar collaboration with Merck & Co. (MSD) is not just validation—it is externalization of their R&D engine. Other pharmas are now effectively plugging into Daiichi Sankyo’s architecture.

The strategic priorities are clear:

• Multi-specific antibodies → increasing targeting precision
• Next-generation payloads → overcoming resistance mechanisms
• Manufacturing scale → biologics as infrastructure, not bottleneck

What they are building resembles less a pipeline and more a biological foundry.

Outro: The Engineering of Precision Medicine

Daiichi Sankyo’s story forces a reframing of innovation.

This is not a tale of disruption—it is a case study in engineering discipline applied to biology over decades.

They didn’t invent the concept of a “guided missile” therapy. They made it work—by solving each subsystem failure, one at a time, across generations of scientists.

For the scientific operator, the takeaway is blunt:

If you control the delivery system, you control the outcome.

From Takamine’s enzymes to DXd payloads, Daiichi Sankyo has been solving the same problem for over a century: how to deliver a biological effect with precision.

Everything else is just iteration.

This has been Petri Dish Perspectives. I’m Manead. Thanks for listening. See you next Thursday. Good bye.

References

1. www.wikipedia.org
2. https://www.daiichisankyo.com/ 
3. https://www.fiercebiotech.com/ 
4. https://finance.yahoo.com/ 
5. https://endpoints.news/